Iridex Corporation develops, manufactures, and markets laser-based medical systems, delivery devices, procedure probes, accessories, and consumable instrumentation for ophthalmology. Its products support treatment of glaucoma, diabetic macular edema, and other retinal diseases, with proprietary MicroPulse® technology used across parts of its portfolio.
Iridex news commonly covers quarterly and annual financial results, business updates, product-family activity for systems such as Cyclo G6®, retina laser platforms including PASCAL®, IQ 532®, IQ 577®, and OcuLight® TX, and clinical literature involving MicroPulse transscleral laser therapy. Company updates also address commercial partnerships, U.S. direct sales, international distributor activity, operational efficiency measures, and Nasdaq listing-status matters.
Iridex (Nasdaq: IRIX) will report fourth quarter and full year 2025 financial results on March 26, 2026 after market close and provide a business update.
Management will host a conference call on March 26, 2026 at 2:00 p.m. PT / 5:00 p.m. ET with live and recorded webcast access on the company website.
Iridex (Nasdaq: IRIX) announced plans to relocate its headquarters from Mountain View, CA to San Jose, CA, under a non-binding letter of intent dated Jan 26, 2026. The company expects to occupy a 31,000 square foot location and forecasted savings of $0.4 million in fiscal 2026 and $0.6 million annualized.
The Lease terms remain subject to change and may not be executed as currently described; the company said the move aims to lower operating expenses while maintaining reduced manufacturing operations and Bay Area talent.
Iridex (NASDAQ: IRIX) reported preliminary unaudited results for the quarter and year ended Jan 3, 2026. Q4 2025 revenue is expected to be $14.6M–$14.8M, up 15%–17% year‑over‑year. The company achieved positive cash flow in Q4 and sold 15,800 Cyclo G6 probes (vs. 13,300 prior year). Full‑year 2025 revenue is expected to be $52.5M–$52.7M (about 8% growth). Iridex expects to achieve positive adjusted EBITDA for 2025. Results remain preliminary and subject to final close and audit.
Iridex (Nasdaq: IRIX) announced publication of an independent retrospective study in Ophthalmology and Therapy showing that retreatment with MicroPulse TLT safely and effectively lowers intraocular pressure (IOP) in glaucoma patients.
The study of 76 eyes at University Eye Clinic Maastricht found meaningful IOP reductions ~25%–35% at three months after retreatment across patient groups. Retreatment timing varied from about 4 months to > 28 months, with second-retreatment intervals of ~3 months to 2 years, supporting repeatability and flexible use in real-world practice.
Iridex (Nasdaq: IRIX) announced a newly published computational study in Translational Vision Science & Technology modeling thermal dynamics of transscleral glaucoma lasers.
The Monte Carlo simulations compared continuous-wave TSCPC (CW-TSCPC) and MicroPulse TLT using Iridex Cyclo G6, G-Probe and MicroPulse P3. Results: CW-TSCPC produced a ~2 mm thermal zone with temperatures >100°C for ~2.2 seconds, while MicroPulse TLT produced a smaller 0.6–1.2 mm zone with peak temperatures below 100°C and more uniform heat distribution.
Authors say both techniques lie on a thermal continuum and may serve complementary clinical roles with further optimization.
Iridex (NASDAQ: IRIX) will participate in the Sidoti Year-End Virtual Investor Conference with management presenting on Thursday, December 11, 2025 at 10:45 AM ET. Interested parties can access a live and archived webcast via the company’s Investor Relations Event Calendar at www.IRIDEX.com. The presentation provides investors a direct opportunity to hear company updates and ask questions during the scheduled webcast.
Iridex (NASDAQ: IRIX) reported third quarter 2025 results with revenue of $12.5M, up 8% year‑over‑year, driven by higher Cyclo G6 probe and Pascal retina system sales.
Key metrics: Cyclo G6 revenue $3.5M (+13%), retina revenue $6.7M (+4%), gross profit $4.0M (32.1% margin), operating expenses $5.4M (down 12%), adjusted EBITDA loss $0.131M (improved $1.3M), and cash $5.6M (down $1.2M).
The company expects adjusted EBITDA positive for full‑year 2025 and to achieve cash flow breakeven in Q4 2025.
Iridex (Nasdaq: IRIX) will release third quarter 2025 financial results and provide a business update after market close on Tuesday, November 11, 2025. Management will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET the same day.
Investors can join by dialing +1-888-596-4144 (US) or +1-646-968-2525 (international) and using Conference ID: 1504499. A live and recorded webcast will be posted on the company’s Investors > Event Calendar page at www.iridex.com.
Iridex Corporation (Nasdaq: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases, has successfully regained compliance with Nasdaq's continued listing requirements. The company had received a non-compliance notice on May 14, 2025, due to falling below the minimum stockholders' equity requirement of $2.5 million based on their Q1 2025 10-Q filing.
On August 27, 2025, Nasdaq formally confirmed that Iridex had regained compliance with Rule 5550(b)(1) following the company's Q2 2025 10-Q filing on August 12, 2025, which demonstrated sufficient stockholders' equity. The compliance matter has been resolved and closed.
Iridex (NASDAQ: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases, reported its Q2 2025 financial results. The company achieved total revenue of $13.6 million, representing 7% year-over-year growth and 14% sequential growth.
Key highlights include Cyclo G6 product family revenue of $3.3 million (flat year-over-year), with 13,100 probes and 35 laser systems sold. Retina product revenue grew 10% year-over-year to $8.0 million. The company reduced operating expenses by 28% and achieved its third consecutive quarter of positive non-GAAP adjusted EBITDA. However, gross margin declined to 34.5% from 40.7% in Q2 2024.
The company reported a net loss of $1.0 million ($0.06 per share) and maintains $6.8 million in cash. For 2025, Iridex aims to achieve cash flow breakeven and positive adjusted EBITDA with revenue consistent with 2024 levels.